Fig. 4From: SLC39A6: a potential target for diagnosis and therapy of esophageal carcinomaKaplan–Meier survival curves for patients with overexpressed SLC39A6 and those with low SLC39A6 levels. a ESCC patients with overexpressed SLC39A6 (IS ≥ 5) experienced a significantly shorter survival period after surgery than those with low SLC39A6 levels (IS < 5) (p < 0.01). b Patients with SLC39A6 overexpression had a greater risk of death than those with lower SLC39A6 levels (p < 0.01). c, d Patients with high SLC39A6 expression shows the worse overall survival at stage I + II than those with low-expression (p < 0.05)Back to article page